RecruitingNot Applicable

Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge

South Korea70 participantsStarted 2026-02-02

Plain-language summary

This study aims to evaluate the feasibility, usability, and clinical effectiveness of a digital rehabilitation platform in adult patients discharged from the intensive care unit (ICU). Adult patients aged 19 years or older who stayed in the ICU for more than 48 hours and are capable of using a smartphone will be enrolled from two tertiary hospitals in South Korea. Participants will receive individualized rehabilitation programs using a digital rehabilitation platform ("Tuntun Rehabilitation Assistant") based on their functional status. Rehabilitation will be conducted once daily for up to 30 minutes per session. Physical and cognitive function outcomes will be assessed at baseline, two weeks after intervention initiation, at hospital discharge, and during follow-up when applicable. This prospective cohort study will investigate changes in physical function, mobility, cognitive status, and quality of life, as well as platform usage and safety-related events, to determine the clinical usefulness of digital rehabilitation for ICU survivors.

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 19 years or older. * Admission to the intensive care unit (ICU) for more than 48 hours. * Hospitalization at Asan Medical Center or Seoul National University Bundang Hospital. * Discharge from the ICU at the time of enrollment. * Ownership of a smartphone and ability to operate a digital rehabilitation platform. * Ability to understand the study procedures and provide voluntary written informed consent. Exclusion Criteria: * Medical conditions that contraindicate participation in rehabilitation exercise, as determined by the attending physician. * Severe cognitive impairment or communication difficulties that interfere with understanding or following study instructions. * Unstable medical conditions requiring ongoing intensive medical treatment. * Inability to use a smartphone or digital platform independently. * Refusal to participate or withdrawal of informed consent.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Medical Research Council Sum Score (MRC-SS)

Timeframe: From enrollment to the end of treatment at 2 weeks

Functional Ambulatory Category (FAC)

Timeframe: From enrollment to the end of treatment at 2 weeks

Mini-Mental State Examination (MMSE)

Timeframe: From enrollment to the end of treatment at 2 weeks

EQ-5D-5L

Timeframe: From enrollment to the end of treatment at 2 weeks

EQ-5D VAS

Timeframe: From enrollment to the end of treatment at 2 weeks

SLR time

Timeframe: From enrollment to the end of treatment at 2 weeks

SLR count

Timeframe: From enrollment to the end of treatment at 2 weeks

Trial details

NCT IDNCT07489092

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Won Kim, Associate professor

82+02-3010-1694 duocl79@gmail.com

View on ClinicalTrials.gov More ICU Acquired Weakness (ICUAW) trials

Plain-language summary

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Medical Research Council Sum Score (MRC-SS)

Timeframe: From enrollment to the end of treatment at 2 weeks

Functional Ambulatory Category (FAC)

Timeframe: From enrollment to the end of treatment at 2 weeks

Mini-Mental State Examination (MMSE)

Timeframe: From enrollment to the end of treatment at 2 weeks

EQ-5D-5L

Timeframe: From enrollment to the end of treatment at 2 weeks

EQ-5D VAS

Timeframe: From enrollment to the end of treatment at 2 weeks

SLR time

Timeframe: From enrollment to the end of treatment at 2 weeks

SLR count

Timeframe: From enrollment to the end of treatment at 2 weeks